JP2015119705A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015119705A5 JP2015119705A5 JP2014263739A JP2014263739A JP2015119705A5 JP 2015119705 A5 JP2015119705 A5 JP 2015119705A5 JP 2014263739 A JP2014263739 A JP 2014263739A JP 2014263739 A JP2014263739 A JP 2014263739A JP 2015119705 A5 JP2015119705 A5 JP 2015119705A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- antibody
- dual target
- target antibody
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000009977 dual effect Effects 0.000 claims 12
- 206010028980 Neoplasm Diseases 0.000 claims 9
- 201000011510 cancer Diseases 0.000 claims 6
- 239000003446 ligand Substances 0.000 claims 5
- 210000004027 cell Anatomy 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 claims 3
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 claims 3
- 239000013604 expression vector Substances 0.000 claims 3
- 238000003259 recombinant expression Methods 0.000 claims 3
- BJHCYTJNPVGSBZ-YXSASFKJSA-N 1-[4-[6-amino-5-[(Z)-methoxyiminomethyl]pyrimidin-4-yl]oxy-2-chlorophenyl]-3-ethylurea Chemical compound CCNC(=O)Nc1ccc(Oc2ncnc(N)c2\C=N/OC)cc1Cl BJHCYTJNPVGSBZ-YXSASFKJSA-N 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 230000033115 angiogenesis Effects 0.000 claims 2
- 239000000427 antigen Substances 0.000 claims 2
- 102000036639 antigens Human genes 0.000 claims 2
- 108091007433 antigens Proteins 0.000 claims 2
- -1 c-Met Proteins 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 210000000130 stem cell Anatomy 0.000 claims 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 2
- 102000009075 Angiopoietin-2 Human genes 0.000 claims 1
- 108010048036 Angiopoietin-2 Proteins 0.000 claims 1
- 102000009840 Angiopoietins Human genes 0.000 claims 1
- 108010009906 Angiopoietins Proteins 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 208000005443 Circulating Neoplastic Cells Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 101100481408 Danio rerio tie2 gene Proteins 0.000 claims 1
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 1
- 101150029707 ERBB2 gene Proteins 0.000 claims 1
- 102000009024 Epidermal Growth Factor Human genes 0.000 claims 1
- 101150021185 FGF gene Proteins 0.000 claims 1
- 108091008794 FGF receptors Proteins 0.000 claims 1
- 101001034652 Homo sapiens Insulin-like growth factor 1 receptor Proteins 0.000 claims 1
- 101000916644 Homo sapiens Macrophage colony-stimulating factor 1 receptor Proteins 0.000 claims 1
- 101000692455 Homo sapiens Platelet-derived growth factor receptor beta Proteins 0.000 claims 1
- 101000932478 Homo sapiens Receptor-type tyrosine-protein kinase FLT3 Proteins 0.000 claims 1
- 102100039688 Insulin-like growth factor 1 receptor Human genes 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 102100028198 Macrophage colony-stimulating factor 1 receptor Human genes 0.000 claims 1
- 206010027476 Metastases Diseases 0.000 claims 1
- 101100481410 Mus musculus Tek gene Proteins 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 108010082093 Placenta Growth Factor Proteins 0.000 claims 1
- 102100035194 Placenta growth factor Human genes 0.000 claims 1
- 102100026547 Platelet-derived growth factor receptor beta Human genes 0.000 claims 1
- 101710098940 Pro-epidermal growth factor Proteins 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 102100029986 Receptor tyrosine-protein kinase erbB-3 Human genes 0.000 claims 1
- 101710100969 Receptor tyrosine-protein kinase erbB-3 Proteins 0.000 claims 1
- 102100029981 Receptor tyrosine-protein kinase erbB-4 Human genes 0.000 claims 1
- 101710100963 Receptor tyrosine-protein kinase erbB-4 Proteins 0.000 claims 1
- 102100020718 Receptor-type tyrosine-protein kinase FLT3 Human genes 0.000 claims 1
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 229920002684 Sepharose Polymers 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 108010053096 Vascular Endothelial Growth Factor Receptor-1 Proteins 0.000 claims 1
- 108010053100 Vascular Endothelial Growth Factor Receptor-3 Proteins 0.000 claims 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims 1
- 102100033178 Vascular endothelial growth factor receptor 1 Human genes 0.000 claims 1
- 102100033179 Vascular endothelial growth factor receptor 3 Human genes 0.000 claims 1
- 206010064930 age-related macular degeneration Diseases 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 208000037976 chronic inflammation Diseases 0.000 claims 1
- 230000006020 chronic inflammation Effects 0.000 claims 1
- 210000002358 circulating endothelial cell Anatomy 0.000 claims 1
- 238000003776 cleavage reaction Methods 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 238000004440 column chromatography Methods 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 210000002889 endothelial cell Anatomy 0.000 claims 1
- 230000003511 endothelial effect Effects 0.000 claims 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims 1
- 102000052178 fibroblast growth factor receptor activity proteins Human genes 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 230000002489 hematologic effect Effects 0.000 claims 1
- 238000004128 high performance liquid chromatography Methods 0.000 claims 1
- 102000006495 integrins Human genes 0.000 claims 1
- 108010044426 integrins Proteins 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 230000009401 metastasis Effects 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims 1
- 230000003472 neutralizing effect Effects 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 201000001514 prostate carcinoma Diseases 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 206010038038 rectal cancer Diseases 0.000 claims 1
- 201000001275 rectum cancer Diseases 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 230000007017 scission Effects 0.000 claims 1
- 238000001542 size-exclusion chromatography Methods 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 210000002536 stromal cell Anatomy 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- 210000004881 tumor cell Anatomy 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR10-2009-0044032 | 2009-05-20 | ||
| KR1020090044032A KR101224468B1 (ko) | 2009-05-20 | 2009-05-20 | 신규한 형태의 이중표적항체 및 그 용도 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012511742A Division JP5744012B2 (ja) | 2009-05-20 | 2009-07-22 | 新規な形態の二重標的抗体およびその使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015119705A JP2015119705A (ja) | 2015-07-02 |
| JP2015119705A5 true JP2015119705A5 (https=) | 2015-11-12 |
Family
ID=43126324
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012511742A Expired - Fee Related JP5744012B2 (ja) | 2009-05-20 | 2009-07-22 | 新規な形態の二重標的抗体およびその使用 |
| JP2014263739A Pending JP2015119705A (ja) | 2009-05-20 | 2014-12-26 | 新規な形態の二重標的抗体およびその使用 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012511742A Expired - Fee Related JP5744012B2 (ja) | 2009-05-20 | 2009-07-22 | 新規な形態の二重標的抗体およびその使用 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US10125194B2 (https=) |
| EP (1) | EP2433968B1 (https=) |
| JP (2) | JP5744012B2 (https=) |
| KR (1) | KR101224468B1 (https=) |
| CN (1) | CN102428104B (https=) |
| AU (1) | AU2009346447B2 (https=) |
| BR (1) | BRPI0924535B1 (https=) |
| CA (1) | CA2762555C (https=) |
| DK (1) | DK2433968T3 (https=) |
| ES (1) | ES2605604T3 (https=) |
| RU (1) | RU2520824C2 (https=) |
| SG (1) | SG175971A1 (https=) |
| WO (1) | WO2010134666A1 (https=) |
Families Citing this family (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9540443B2 (en) | 2011-01-26 | 2017-01-10 | Kolltan Pharmaceuticals, Inc. | Anti-kit antibodies |
| KR20120130658A (ko) * | 2011-05-23 | 2012-12-03 | 주식회사 파멥신 | 펩타이드가 융합된 이중표적항체 및 그 용도 |
| WO2013075740A1 (en) | 2011-11-23 | 2013-05-30 | Sanofi | Antibody purification method |
| KR102274211B1 (ko) | 2011-11-23 | 2021-07-09 | 인3바이오 리미티드 | 재조합 단백질 및 그들의 치료적 용도 |
| CN116574185A (zh) | 2012-07-25 | 2023-08-11 | 塞尔德克斯医疗公司 | 抗kit抗体及其用途 |
| DK2924052T3 (da) * | 2012-11-21 | 2019-09-30 | Pharmabcine Inc | Dual-target-antistof målrettet mod vegfr-2 og dll4, og farmaceutisk sammensætning omfattende samme |
| WO2014108854A1 (en) | 2013-01-09 | 2014-07-17 | Fusimab Ltd. | Monospecific anti-hgf and anti-ang2 antibodies and bispecific anti-hgf/anti-ang2 antibodies |
| KR102049991B1 (ko) | 2013-03-28 | 2019-12-02 | 삼성전자주식회사 | 항 c-Met/항 Her2 이중 특이 항체 |
| KR102074421B1 (ko) | 2013-03-29 | 2020-02-10 | 삼성전자주식회사 | 항 c-Met/항 EGFR 이중 특이 항체 |
| KR102060540B1 (ko) | 2013-04-03 | 2019-12-31 | 삼성전자주식회사 | 항 c-Met 항체 및 항 Ang2 항체를 포함하는 병용 투여용 약학 조성물 |
| NO2994485T3 (https=) * | 2013-05-06 | 2018-06-09 | ||
| KR20150063728A (ko) * | 2013-12-02 | 2015-06-10 | 삼성전자주식회사 | 항 VEGF-C/항 Ang2 이중 특이 항체 |
| KR102223502B1 (ko) | 2014-05-09 | 2021-03-05 | 삼성전자주식회사 | 항 c-Met/항 EGFR/항 Her3 다중 특이 항체 및 이의 이용 |
| AR100271A1 (es) * | 2014-05-19 | 2016-09-21 | Lilly Co Eli | Compuestos de vegfr2 / ang2 |
| CN113908269A (zh) | 2014-05-23 | 2022-01-11 | 塞尔德克斯医疗公司 | 嗜酸性粒细胞或肥大细胞相关病症的治疗 |
| KR20160024639A (ko) | 2014-08-26 | 2016-03-07 | 삼성전자주식회사 | c-Met 표적 치료제의 저항성 또는 효능 예측을 위한 바이오마커 PDGF |
| WO2016060297A1 (ko) * | 2014-10-16 | 2016-04-21 | 주식회사 파멥신 | VEGFR-2 및 c-Met에 대하여 결합성을 갖는 이중표적항체 |
| KR102309881B1 (ko) | 2014-11-21 | 2021-10-06 | 삼성전자주식회사 | c-Met 및 EGFR의 이중 저해제 및 IGF-1R 저해제를 포함하는 병용 투여용 약학 조성물 |
| CN107660214B (zh) | 2015-01-08 | 2022-02-08 | 根马布股份公司 | 针对cd3和cd20的双特异性抗体 |
| CN108368172B (zh) | 2015-07-15 | 2022-06-14 | 根马布股份公司 | 人源化或嵌合cd3抗体 |
| SG11201811431VA (en) | 2016-07-14 | 2019-01-30 | Genmab As | Multispecific antibodies against cd40 and cd137 |
| CN110312735A (zh) * | 2016-09-08 | 2019-10-08 | 宇里技术有限公司 | 特异性地结合至clec14a的去糖基化抗体及其用途 |
| BR112019018533A2 (pt) | 2017-03-09 | 2020-04-14 | Genmab A/S | anticorpo, construção de ácido nucleico, vetor de expressão, célula hospedeira, composição farmacêutica, método para tratar uma doença, e, uso de um anticorpo |
| EP3601354A1 (en) | 2017-03-31 | 2020-02-05 | Genmab Holding B.V. | Bispecific anti-cd37 antibodies, monoclonal anti-cd37 antibodies and methods of use thereof |
| SG11202000198QA (en) | 2017-08-04 | 2020-02-27 | Genmab As | Binding agents binding to pd-l1 and cd137 and use thereof |
| CN112055718A (zh) * | 2018-03-19 | 2020-12-08 | 药物抗体公司 | 抗vegfr-2抗体 |
| JP7339325B2 (ja) * | 2018-03-20 | 2023-09-05 | ナショナル ヘルス リサーチ インスティテューツ | 単離抗体、医薬組成物、単離抗体結合体、ダイマー化阻害方法、シグナル伝達阻害方法、管新生阻害方法、治療方法、および断片検出方法 |
| CN111902720B (zh) * | 2018-03-21 | 2025-02-07 | 沃特世科技公司 | 基于非抗体高亲和力的样品制备、吸附剂、装置和方法 |
| EP3546475A1 (en) | 2018-03-27 | 2019-10-02 | Sanofi | Full flow-through process for purifying recombinant proteins |
| WO2020060406A1 (en) | 2018-09-19 | 2020-03-26 | Lava Therapeutics B.V. | Novel bispecific antibodies for use in the treatment of hematological malignancies |
| MA53812A (fr) | 2018-10-04 | 2021-08-11 | Genmab Holding B V | Compositions pharmaceutiques comprenant des anticorps anti-cd37 bispécifiques |
| US20210369842A1 (en) | 2018-11-06 | 2021-12-02 | Genmab A/S | Antibody formulation |
| NL2022494B1 (en) | 2019-02-01 | 2020-08-19 | Lava Therapeutics B V | Novel CD40-binding antibodies |
| CN113993893A (zh) | 2019-02-01 | 2022-01-28 | 拉法医疗有限公司 | 新cd40结合抗体 |
| JP7447144B2 (ja) * | 2019-08-14 | 2024-03-11 | ファームアブシン・インコーポレイテッド | 抗ｔｉｅ２抗体及びその用途 |
| EP3792283A1 (en) | 2019-09-16 | 2021-03-17 | Lava Therapeutics B.V. | Treatment of cancer comprising administration of vgamma9vdelta2 t cell receptor binding antibodies |
| WO2021155916A1 (en) | 2020-02-04 | 2021-08-12 | BioNTech SE | Treatment involving antigen vaccination and binding agents binding to pd-l1 and cd137 |
| CA3168613A1 (en) | 2020-03-18 | 2021-09-23 | Genmab A/S | Antibodies binding to b7h4 |
| CA3176436A1 (en) | 2020-05-08 | 2021-11-11 | Tahamtan Ahmadi | Bispecific antibodies against cd3 and cd20 |
| CN116323667A (zh) | 2020-07-08 | 2023-06-23 | 拉法医疗股份有限公司 | 结合PSMA和γ-δT细胞受体的抗体 |
| EP4192859A1 (en) | 2020-08-06 | 2023-06-14 | BioNTech SE | Binding agents for coronavirus s protein |
| AU2021342342A1 (en) | 2020-09-10 | 2023-04-13 | Genmab A/S | Bispecific antibodies against CD3 and CD20 for treating chronic lymphocytic leukemia |
| IL301085A (en) | 2020-09-10 | 2023-05-01 | Genmab As | A bispecific antibody against CD3 and CD20 in combination therapy for the treatment of diffuse large B-cell lymphoma |
| CN119792512A (zh) | 2020-10-14 | 2025-04-11 | 维里迪安治疗公司 | 用于治疗甲状腺眼病的组合物和方法 |
| IL303045A (en) | 2020-12-10 | 2023-07-01 | Lava Therapeutics N V | Antibodies that bind gamma-delta t cell receptors |
| MX2023009950A (es) | 2021-02-26 | 2023-11-10 | Lava Therapeutics N V | Anticuerpos que se unen a cd123 y receptores de linfocitos t gamma-delta. |
| IL308300A (en) | 2021-05-07 | 2024-01-01 | Genmab As | PHARMACEUTICAL COMPOSITIONS COMPRISING BISPECIFIC ANTIBODIES BINDING TO B7H4 and CD3 |
| JP2024523438A (ja) | 2021-06-21 | 2024-06-28 | ジェンマブ エー／エス | Ｃｄ１３７結合物質とｐｄ－ｌ１結合物質の組合せ投薬レジメン |
| TW202320850A (zh) | 2021-08-10 | 2023-06-01 | 美商維里迪恩醫療股份有限公司 | 用於治療甲狀腺眼病之組合物、劑量及方法 |
| WO2023037333A1 (en) | 2021-09-13 | 2023-03-16 | Janssen Biotech, Inc | CD33 X Vδ2 MULTISPECIFIC ANTIBODIES FOR THE TREATMENT OF CANCER |
| AR127298A1 (es) | 2021-10-08 | 2024-01-10 | Genmab As | Anticuerpos que se unen a cd30 y cd3 |
| JP2024538958A (ja) | 2021-10-21 | 2024-10-28 | ラヴァ・セラピューティクス・エヌ・ヴイ | ガンマデルタｔ細胞活性化抗体の使用 |
| WO2023174521A1 (en) | 2022-03-15 | 2023-09-21 | Genmab A/S | Binding agents binding to epcam and cd137 |
| EP4285926A1 (en) | 2022-05-30 | 2023-12-06 | LAVA Therapeutics N.V. | Combination treatment for chronic lymphocytic leukemia |
| EP4292609A1 (en) | 2022-06-15 | 2023-12-20 | LAVA Therapeutics N.V. | Compositions comprising antibodies that bind gamma-delta t cell receptors |
| EP4292610A1 (en) | 2022-06-15 | 2023-12-20 | LAVA Therapeutics N.V. | Variant antibodies that bind gamma-delta t cell receptors |
| NL2032398B1 (en) | 2022-07-06 | 2024-01-23 | Academisch Ziekenhuis Leiden | Bispecific antibody and uses thereof |
| WO2024200573A1 (en) | 2023-03-27 | 2024-10-03 | LAVA Therapeutics N.V. | Nectin-4 binding agents and methods of use |
| EP4438624A1 (en) | 2023-03-27 | 2024-10-02 | LAVA Therapeutics N.V. | Antibodies that bind nectin-4 and gamma-delta t cell receptors |
| WO2024208898A1 (en) | 2023-04-05 | 2024-10-10 | Genmab A/S | Pharmaceutical compositions comprising antibodies binding to cd30 and cd3 |
| AR133071A1 (es) | 2023-06-30 | 2025-08-20 | Genmab As | ANTICUERPOS QUE SE UNEN A LA PROTEÍNA DE ACTIVACIÓN DE FIBROBLASTOS a Y AL RECEPTOR DE MUERTE 4 |
| WO2025012118A2 (en) | 2023-07-07 | 2025-01-16 | LAVA Therapeutics N.V. | 5t4 binding agents and methods of use |
| TW202519261A (zh) | 2023-07-27 | 2025-05-16 | 荷蘭商拉法醫療公司 | 用於治療癌症之結合γ-δ T細胞受體之抗體 |
| WO2025056180A1 (en) | 2023-09-15 | 2025-03-20 | BioNTech SE | Methods of treatment using agents binding to epcam and cd137 in combination with pd-1 axis binding antagonists |
| WO2026078231A1 (en) | 2024-10-11 | 2026-04-16 | T-Therapeutics Limited | Soluble non-aggregating immune ligand |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| ATE300615T1 (de) | 1990-08-29 | 2005-08-15 | Genpharm Int | Transgene mäuse fähig zur produktion heterologer antikörper |
| CA2405246A1 (en) | 1990-12-03 | 1992-06-11 | Genentech, Inc. | Enrichment method for variant proteins with alterred binding properties |
| DK0642585T3 (da) | 1992-05-18 | 2006-05-15 | Genentech Inc | Aktiviering af oligomeriserende receptorer ved anvendelse af fusionerede receptorligander |
| US5942602A (en) * | 1997-02-13 | 1999-08-24 | Schering Aktiengessellschaft | Growth factor receptor antibodies |
| EP1179541B1 (en) * | 1999-04-28 | 2004-06-16 | Board Of Regents, The University Of Texas System | Compositions and methods for cancer treatment by selectively inhibiting VEGF |
| US7090843B1 (en) * | 2000-11-28 | 2006-08-15 | Seattle Genetics, Inc. | Recombinant anti-CD30 antibodies and uses thereof |
| SI1916001T1 (sl) | 2002-03-04 | 2011-10-28 | Imclone Llc | Äśloveĺ ka protitelesa specifiäśna za kdr in njihova uporaba |
| AU2003224073C1 (en) * | 2002-04-22 | 2010-03-11 | AgroProtect GmbH | Antibodies, recombinant antibodies, recombinant antibody fragments and fusions mediated plant disease resistance against fungi |
| AU2004215653B2 (en) | 2003-02-28 | 2011-03-17 | Lonza Biologics Plc. | Antibody purification by protein A and ion exchange chromatography |
| US20090111146A1 (en) | 2003-09-02 | 2009-04-30 | National Institute Of Advanced Industrial Science | Antibody Drug |
| CN100503640C (zh) * | 2004-07-08 | 2009-06-24 | 中国人民解放军军事医学科学院生物工程研究所 | 一种抗肿瘤融合蛋白及其编码基因与应用 |
| WO2006005361A1 (en) | 2004-07-13 | 2006-01-19 | Centre National De La Recherche Scientifique | Peptides liable to bind to the tie2 receptor, nucleic acids encoding them, and their uses |
| US20060058311A1 (en) * | 2004-08-14 | 2006-03-16 | Boehringer Ingelheim International Gmbh | Combinations for the treatment of diseases involving cell proliferation |
| CN1884300A (zh) * | 2005-06-24 | 2006-12-27 | 中国人民解放军军事医学科学院微生物流行病研究所 | 一种具有靶向功能的抗肝癌超抗原,其制备方法及用途 |
| WO2008090958A1 (ja) | 2007-01-24 | 2008-07-31 | Kyowa Hakko Kirin Co., Ltd. | ドメイン交換された遺伝子組換え抗体組成物 |
| KR100883430B1 (ko) * | 2007-06-13 | 2009-02-12 | 한국생명공학연구원 | 혈관내피성장인자 수용체를 중화하는 인간 단클론항체 및그 용도 |
| KR102060540B1 (ko) * | 2013-04-03 | 2019-12-31 | 삼성전자주식회사 | 항 c-Met 항체 및 항 Ang2 항체를 포함하는 병용 투여용 약학 조성물 |
-
2009
- 2009-05-20 KR KR1020090044032A patent/KR101224468B1/ko not_active Expired - Fee Related
- 2009-07-22 US US13/319,899 patent/US10125194B2/en active Active
- 2009-07-22 EP EP09844974.7A patent/EP2433968B1/en active Active
- 2009-07-22 BR BRPI0924535-9A patent/BRPI0924535B1/pt not_active IP Right Cessation
- 2009-07-22 SG SG2011082542A patent/SG175971A1/en unknown
- 2009-07-22 JP JP2012511742A patent/JP5744012B2/ja not_active Expired - Fee Related
- 2009-07-22 CN CN200980159382.XA patent/CN102428104B/zh not_active Expired - Fee Related
- 2009-07-22 CA CA2762555A patent/CA2762555C/en active Active
- 2009-07-22 DK DK09844974.7T patent/DK2433968T3/en active
- 2009-07-22 AU AU2009346447A patent/AU2009346447B2/en not_active Ceased
- 2009-07-22 ES ES09844974.7T patent/ES2605604T3/es active Active
- 2009-07-22 RU RU2011146088/10A patent/RU2520824C2/ru active
- 2009-07-22 WO PCT/KR2009/004084 patent/WO2010134666A1/ko not_active Ceased
-
2014
- 2014-12-26 JP JP2014263739A patent/JP2015119705A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015119705A5 (https=) | ||
| RU2011146088A (ru) | Антитело двойной направленности в новой форме и его применение | |
| RU2509085C2 (ru) | Стабилизированные антитела против ангиопоэтина-2 и их применение | |
| FI3345613T3 (fi) | Koostumus käytettäväksi syövän tai angiogeneesiin liittyvän sairauden hoidossa käsittäen tuumoriin penetroituvan peptidin ja VEGF-estäjän fuusioproteiinin | |
| JP2015516801A5 (https=) | ||
| EA202092735A1 (ru) | Антагонизирующее cd73 антитело | |
| CY1125797T1 (el) | Μεθοδοι και συνθεσεις για τη θεραπευτικη αντιμετωπιση του καρκινου | |
| CL2011003182A1 (es) | Anticuerpo anti-vegf o fragmento de union del mismo que comprende cdrs con secuencias aminoacidicas con hasta 17 mutaciones respecto a las secuencias cdrs del anticuerpo bavacizumab o ranibizumab; acido nucleico; vector; celula huesped; metodo de produccion; conjugado anticuerpo-farmaco; composicion; y uso para tratar cancer. | |
| EA201300311A1 (ru) | Vegf-связывающие молекулы | |
| CL2014000181A1 (es) | Anticuerpo monoclonal capaz de inhibir la dimerización de receptor para el factor del crecimiento de hepatocitos (c-met); acido nucleico aislado que lo codifica; vector y célula huesped que lo comprenden; proceso para la produccion del anticuerpo; uso del anticuerpo para tratar cancer (divisional de la solicitud 1296-11). | |
| EA201591515A1 (ru) | Полипептиды il-22, химерные белки il-22 fc и их применение | |
| EA201990017A1 (ru) | Антитела к миостатину и способы их применения | |
| JP2016516789A5 (https=) | ||
| EA201891420A1 (ru) | Антитела к миостатину, полипептиды, содержащие варианты fc-областей, и способы их применения | |
| PE20181044A1 (es) | Anticuerpos anti-pd-1 y composiciones | |
| FI3354729T3 (fi) | Anti-garp-vasta-aine | |
| EA202091198A1 (ru) | Полипептиды, содержащие домен d, и их применение | |
| EP2579895A4 (en) | ANTI-VEGF ANTIBODIES AND USES THEREOF | |
| EA201890294A1 (ru) | Химерный полипептидный комплекс и способы его получения и применения | |
| EA201891641A1 (ru) | Химерные антигенные рецепторы, нацеленные на вариант iii рецептора эпидермального фактора роста | |
| EA201791253A1 (ru) | Антитела к миостатину, полипептиды, содержащие варианты fc-областей, и способы их применения | |
| UA118096C2 (uk) | ВИДІЛЕНА БІСПЕЦИФІЧНА МОЛЕКУЛА, ЩО ЗВ'ЯЗУЄТЬСЯ З ДОМЕНОМ ФІБРОНЕКТИНУ ІІІ ТИПУ EGFR I c-Met | |
| EA200970700A1 (ru) | Ингибиторы киназы, пригодные для лечения миелопролиферативных заболеваний и других пролиферативных заболеваний | |
| EA201691304A1 (ru) | АНТАГОНИСТЫ НЕОНАТАЛЬНЫХ Fc-РЕЦЕПТОРОВ (FcRn) И СПОСОБЫ ИХ ПРИМЕНЕНИЯ | |
| EA201791366A1 (ru) | Антитела к c5 и способы их применения |